

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Docket No. 13115; API-02-06-US)

In the Application of:)
)
 Berinstein, et al.)
) **Examiner: Anne Marie Sabrina Wehbe**
 Serial No. 09/693,754)
) **Art Unit: 1633**
 Filing Date: 10/20/2000)
)
 Title: Methods of Inducing and / or)
 Enhancing an Immune Response)
 To Tumor Antigens)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted via EFS-Web

Supplemental Information Disclosure Statement Under 37 CFR 1.97(c)

Applicants respectfully submit this Supplemental Information Disclosure Statement, PTO-SB08a, and copies of the non-U.S. patent references cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. The Applicant believes no fees are due with this submission; if this is in error, the undersigned hereby authorizes the Commissioner to deduct any required fees from Deposit Account No. 50-0244. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

CITED REFERENCES

U.S. patents and published applications

6709844
6861234
6977074
6994851
7232682
7364729
7390654
20020025578A1

Non-U.S. Patent Documents

EP1083232A1

Other Documents

HADZANTONIS, et al. Dendritic Cell Immunotherapy for Melanoma. Cancer Biotherapy & Radiopharmaceuticals, 14:11-22 (1999)

FINTOR, et al. Melanoma Vaccine Momentum Spurs Interest, Investment. J. Natl. Cancer Inst. 92: 1205-1207 (2000)

GHOSE, et al. Immunogenecity of Whole-Cell Tumor Preparations Infected with the ALVAC Viral Vector. Human Gene Ther. 11: 1289-1301 (2000)

Respectfully Submitted,

Date: April 1, 2011

By: /Patrick J. Halloran/
Patrick J. Halloran
Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D.
3141 Muirfield Road
Center Valley, PA 18034
Tel: 610-984-4751
Fax: 484-214-0164